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The prognostic significance of blood pressure (BP) vari-ability remains controversial. Some studies reported asso-
ciation of end-organ damage,1–4 cardiovascular events,5–7 or 
mortality8 with BP variability, whereas others failed to do so 
or found variability to be inferior to level of systolic BP.9–11 
Whether naturally occurring BP variability predicts risk over 
and beyond BP level therefore remains debated. Part of the 
contradiction in the current literature1–11 might find its origin 
in the technique used to measure BP, the interval over which 
BP variability is assessed, and the statistical indices applied 
to capture BP variability from recordings.12 Expert opinion 
converges on the concept that  beat-to-beat recordings are opti-
mal to capture short-term BP variability, whereas intermittent 
ambulatory BP monitoring is less precise.13 To our knowledge, 
no previous study assessed target organ damage in relation to 
beat-to-beat, reading-to-reading, and day-to-day BP variabil-
ity. In addition, experts proposed avoiding measures of vari-
ability that are dependent on the BP level, such as the SD.14,15
To address the above issues, we ran multivariable-adjusted 
linear regression analyses to correlate left ventricular mass 
index (LVMI), the urinary albumin-to-creatinine ratio, and 
aortic pulse wave velocity (PWV) as continuous measures of 
target organ damage with BP level and variability in untreated 
Chinese patients referred to an outpatient clinic. We measured 
BP by 10-minute beat-to-beat recordings, 24-hour ambula-
tory registration, and home readings self-measured for 7 
days. From these data sources, we quantified variability using 
recently proposed novel indices.14,15
Methods
Study Population
As described previously,16 we recruited consecutive untreated 
patients referred for ambulatory BP monitoring to the Hypertension 
Outpatient Clinic of Ruijin Hospital, Shanghai, China. We adhere to 
the principles of the Declaration of Helsinki, and the study protocol 
was approved by the Ethics Committee of Ruijin Hospital, Shanghai 
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Jiaotong University School of Medicine. All patients gave informed 
written consent. Of those referred between February 2011 and 
December 2011, 259 were eligible for inclusion in the present analy-
sis because they all had beat-to-beat, 24-hour ambulatory, and home 
BP measurements. The primary reason for referral was diagnosis of 
the BP status by 24-hour ambulatory BP monitoring in 236 (91.1%) 
never treated participants or confirmation of the indication for antihy-
pertensive drug treatment in 23 (8.9%) patients after ≥2 weeks of dis-
continuation of antihypertensive agents. We excluded 3 patients from 
the analysis because the indices of organ damage were >3 SDs higher 
than the mean. Thus, the number of participants analyzed totaled 256.
BP Measurement
We programmed validated oscillometric SpaceLabs 90217 monitors 
(SpaceLabs, Redmond, Washington) to obtain ambulatory BP read-
ings at 20-minute intervals from 06:00 to 22:00 and at  30-minute 
intervals from 22:00 to 06:00. Ambulatory hypertension was a 
24-hour BP averaging 130 mm Hg systolic or 80 mm Hg diastolic or 
more. Office BP was measured with the Omron HEM-7051 monitor 
(Omron HealthCare, Kyoto, Japan). Office hypertension was a BP of 
≥140 mm Hg systolic or 90 mm Hg diastolic. Using the BP monitor 
of the same type as in the office, participants obtained BP readings 
at home in triplicate in the morning before breakfast and again 3× in 
the evening before going to sleep during 7 consecutive days. Home 
hypertension was a BP of 135 mm Hg systolic or 85 mm Hg diastolic 
or more. Within 7 days after 24-hour BP monitoring, we recorded 
the beat-to-beat finger BP for 10 minutes with the Finometer device 
(Finapres Medical System, Amsterdam, The Netherlands). For fur-
ther details of the BP measurement, see Expanded Methods in the 
online-only Data Supplement.
Assessment of Organ Damage
As described in detail elsewhere,16 LVMI by echocardiography 
(n=128), the urinary albumin-to-creatinine ratio (n=256), and aortic 
PWV (n=255) were determined as measures of organ damage. For 
the details of the organ damage assessment and other measurements, 
including body mass index, serum cholesterol, plasma glucose, and 
questionnaire survey on smoking and drinking habits, see Expanded 
Methods in the online-only Data Supplement.
Statistical Analysis
For database management and statistical analysis, we used the 
Statistical Analysis System software, version 9.3 (SAS Institute, 
Cary, NC). We limited our main analyses to systolic BP because 
systolic BP is the main driver of risk17 and because we recently dem-
onstrated in the same patient cohort that systolic BP was the main 
determinant of target organ damage irrespective of age.16 Henceforth, 
in our article unless otherwise specified, BP refers to systolic BP. 
We assessed BP variability from the variability independent of the 
mean (VIM),15 the difference between maximum and minimum BP 
(MMD), and average real variability (ARV).10,14 For the details of the 
computation of these variability indices, see Expanded Methods in 
the online-only Data Supplement.
To study the association between organ damage and BP level and 
variability, we first searched for covariables associated with BP vari-
ability in stepwise regression analysis with P values for explanatory 
variables to enter and stay in models set at 0.15. Next, we used multi-
ple regression analysis to study the association of interest while adjust-
ing for sex, age, body mass index, heart rate, fasting plasma glucose, 
total cholesterol, and smoking and drinking. Fully adjusted models 
included both BP level and an index of BP variability. We computed 
the variance inflation factor to assess to what extent parameter esti-
mates for BP level and variability were affected by collinearity in fully 
adjusted regression models. Significance was an α-level of ≤0.05.
Results
Characteristics of the Participants
The 256 participants included 129 women (50.4%) and 17 
(6.6%) patients with diabetes mellitus. Among women, the 
Table 1. Characteristics of Participants by Blood Pressure Measurement Type and Median of Variability Independent of the Mean
Characteristic
Finger Blood Pressure 24-H Blood Pressure Home Blood Pressure
<6.8 U ≥6.8 U <13.6 U ≥13.6 U <4.7 U ≥4.7 U
No. of subjects (%) 128 (50.0) 128 (50.0) 129 (50.4) 127 (49.6) 126 (49.2) 130 (50.8)
  Women 58 (45.3) 71 (55.5) 60 (46.5) 69 (54.3) 47 (37.3) 82 (63.1)*
  Smokers 28 (21.9) 24 (18.9) 26 (20.2) 26 (20.5) 35 (27.8) 17 (13.1)†
  Drinking alcohol 22 (17.2) 21 (16.4) 19 (14.7) 24 (18.9) 22 (17.5) 21 (16.2)
  Diabetes mellitus 11 (8.6) 6 (4.7) 10 (7.8) 7 (5.5) 5 (4.0) 12 (9.2)
Mean characteristic (±SD)
  Age, y 51.2±10.7 50.9±10.0 49.5±10.4 52.6±10.0‡ 48.5±10.7 53.5±9.2*
  Body mass index, kg/m2 24.5±2.5 24.5±3.1 24.7±2.5 24.3±3.0 24.7±2.9 24.3±2.7
  Systolic blood pressure, mm Hg 137.3±13.1 136.1±12.3 125.9±12.3 126.5±11.2 128.9±10.7 128.0±12.0
  Diastolic blood pressure, mm Hg 77.8±7.8 76.1±8.4 82.1±10.1 81.3±9.3 82.4±9.2 78.5±8.7*
  Heart rate, bpm 69.7±8.6 68.9±8.7 71.7±7.4 72.6±7.6 71.4±7.5 69.9±7.7
  Maximum–minimum difference, mm Hg 34.6±11.5 56.8±27.2* 53.3±8.6 72.0±11.8* 9.8±2.6 18.9±5.7*
  Average real variability, mm Hg 2.3±0.8 2.8±1.0* 8.6±1.4 9.9±1.6* 3.8±1.3 6.5±2.1*
  Plasma glucose, mmol/L 4.94±0.85 5.12±1.06 5.04±1.11 5.02±0.80 5.04±1.09 5.02±0.83
  Serum total cholesterol, mmol/L 4.93±0.78 4.99±0.93 4.85±0.90 5.07±0.81‡ 4.93±0.89 4.99±0.83
  Left ventricular mass index, g/m2 92.7±14.4 96.0±16.7 94.1±16.0 94.6±15.1 92.4±15.5 96.3±15.5
  Aortic pulse wave velocity, m/s 7.8±1.5 7.6±1.2 7.5±1.3 7.9±1.4‡ 7.7±1.4 7.7±1.3
  Albumin-to-creatinine ratio, mg/mmol 0.60 (0.16–2.51) 0.68 (0.17–3.86) 0.66 (0.16–2.97) 0.62 (0.18–2.94) 0.61 (0.16–3.00) 0.67 (0.18–2.77)
Diabetes mellitus was a plasma glucose level of 7.0 mmol/L or higher or use of antidiabetic drugs. Left ventricular mass index was available in 128 patients. The 
central tendency and spread of the urinary albumin-to-creatinine ratio are geometric mean and 5th to 95th percentile interval. To convert cholesterol and glucose from 
mmol/L to mg/dL, multiply by 38.6 or 18.0, respectively. 
Significance of the difference with values below the midpoint: *P<0.001; †P<0.01; and ‡P<0.05.
792  Hypertension  April 2014
prevalence of smoking and drinking was 0% and 3.9% and 
among men 40.9% and 29.9%, respectively. Age ranged from 
29.1 to 71.3 years, averaging (±SD) 51.1±10.3 years (Figure 
S1 in the online-only Data Supplement). The prevalence of 
hypertension was 27.0%, 63.3%, and 39.8% on office, 24-hour, 
and home BP measurement, respectively. Expanded Results in 
the online-only Data Supplement and Table S1 provide infor-
mation according to the cross-classification of participants 
based on office and out-of-the-office BP measurement and 
information on the quality assurance of the finger, 24-hour, 
and home BP measurement. Table 1 shows the characteristics 
of the participants by the median of the distribution of VIM 
derived from finger, 24-hour, and home BP recordings.
Correlates of the Variability Indices
In unadjusted analyses across quartiles of systolic BP level 
(Figure), VIM did not increase (P≥0.28), irrespective of the 
type of BP measurement. With the exception of MMD in 
beat-to-beat recordings (P=0.21), MMD and ARV increased 
(P≤0.007) across quartiles of systolic BP level.
We assessed the correlations between various indices of BP 
variability within and across measurement type (Table S2). 
As assessed by VIM, reading-to-reading pressure variability 
correlated with beat-to-beat (r=0.15; P=0.015) and  day-to-day 
(r=0.13; P=0.038) variability, whereas the correlation between 
beat-to-beat and day-to-day VIM was low (r=0.01; P=0.89). 
We also performed stepwise regression analysis to identify 
correlates of systolic BP variability by type of BP measure-
ment. The correlates differed for VIM, MMD, and ARV within 
and across measurement type (Table S3). The explained vari-
ance ranged from 2.3% to 26.2%.
Effect Sizes Associated With Level and Variability 
of Systolic BP
Beat-to-Beat Recordings
As shown in Table 2, LVMI was not associated with level of 
systolic BP in beat-to-beat recordings (P≥0.18), but indepen-
dent of systolic BP and other covariables increased with VIM 
(+3.144 g/m2; P=0.005), MMD (+3.528 g/m2; P=0.002), and 
ARV (+2.968 g/m2; P=0.038). The urinary albumin-to-creat-
inine ratio independently increased with the level of systolic 
BP (+1.139–1.169 mg/mmol; P≤0.03) and MMD (+1.183 
mg/mmol; P=0.003). PWV only increased with the level of 
systolic BP (+0.689 m/s; P<0.001). In all models including 
both level and variability of beat-to-beat BP, the variance 
inflation factor did not exceed 1.24.
Figure. Variability independent of the mean (VIM, A), maximum–minimum difference (MMD, B), and average real variability (ARV, C) by 
quartiles of the distribution of the systolic blood pressure (SBP) on beat-to-beat (○, FBPM), 24-hour ambulatory (□, ABPM), or home (∆, 
HBPM) measurement. P values are for linear trend across the quartiles of SBP.
Table 2. Association of Organ Damage With Level and Variability of Systolic Blood Pressure Derived From Beat-to-Beat Recordings
Correlate (Approximate SD) Model Left Ventricular Mass Index, g/m2
Albumin-to-Creatinine  
Ratio, mg/mmol Pulse Wave Velocity, m/s
SBP (+13 mm Hg) None 1.209 (–1.619 to 4.037) 1.169 (1.055 to 1.294)† 0.689 (0.562 to 0.816)*
VIM 1.924 (–0.853 to 4.701) 1.169 (1.055 to 1.294)† 0.689 (0.562 to 0.816)*
MMD 1.456 (–1.270 to 4.182) 1.139 (1.028 to 1.261)‡ 0.689 (0.562 to 0.816)*
ARV 0.533 (–2.321 to 3.387) 1.139 (1.028 to 1.261)‡ 0.689 (0.536 to 0.842)*
VIM (+2 U) None 2.882 (0.753 to 5.011)† 1.051 (0.965 to 1.146) –0.074 (–0.199 to 0.051)
SBP 3.144 (0.992 to 5.296)† 1.051 (0.969 to 1.141) –0.074 (–0.180 to 0.032)
MMD (+24 mm Hg) None 3.480 (1.269 to 5.691)† 1.183 (1.077 to 1.300)† 0.024 (–0.117 to 0.165)
SBP 3.528 (1.317 to 5.739)† 1.183 (1.077 to 1.300)† –0.048 (–0.189 to 0.093)
ARV (+1 mm Hg) None 3.083 (0.386 to 5.780)‡ 1.163 (1.031 to 1.311)‡ 0.234 (0.056 to 0.412)‡
SBP 2.968 (0.195 to 5.741)‡ 1.113 (0.982 to 1.261) –0.006 (–0.167 to 0.155)
Model indicates which systolic index was entered into the models in addition to the predictor variable per se. None indicates that no systolic index was entered in 
addition to the studied predictor variable. Effect sizes (95% confidence interval) express the change in target organ damage associated with a 1-SD increase in the systolic 
predictors. All models were adjusted for sex, age, body mass index, heart rate, plasma glucose, serum cholesterol, and smoking and drinking. ARV indicates average 
real variability; MMD, the difference of maximum minus minimum systolic blood pressure; SBP, systolic blood pressure; and VIM, variability independent of the mean.
Significance of the estimates: *P<0.001; †P<0.01; and ‡P<0.05.
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24-Hour Ambulatory Recordings
As shown in Table 3, independent of the 3 indices of BP 
variability, LVMI (+3.156–3.792 g/m2; P≤0.029), the uri-
nary albumin-to-creatinine ratio (+1.241–1.287 mg/mmol; 
P<0.001), and PWV (+0.360–0.444 m/s; P≤0.001) increased 
with higher level of systolic BP. The associations of organ 
damage with the indices of BP variability were all nonsig-
nificant (P≥0.15) with the exception of an increase in PWV 
with VIM (+0.156 m/s; P=0.045) and MMD (+0.168 m/s; 
P=0.032). In all models including both level and variability of 
the 24-hour BP (Table 3), the variance inflation factor was not 
higher than 1.36. Sensitivity analyses based on daytime (Table 
S4) and nighttime (Table S5) BP were confirmatory.
Self-Measured Home Recordings
As shown in Table 4, independent of the 3 indices of BP vari-
ability, the urinary albumin-to-creatinine ratio (+1.274–1.302 
mg/mmol; P<0.001) and PWV (+0.363–0.396 m/s; P≤0.001), 
but not LVMI (P≥0.43), increased with higher level of sys-
tolic BP. The associations of organ damage with all of the 
indices of BP variability on self-measurement were nonsig-
nificant (P≥0.067). In all models including both level and 
variability of the home BP (Table 4), the variance inflation 
factor was not higher than 1.23. Sensitivity analyses based 
on the morning (Table S6) and evening (Table S7) home BP 
were confirmatory.
Additional Analyses
To allow comparison of our current results with the literature, 
we repeated our analyses using SD and coefficient of variation 
as indices of BP variability (Table S8). The associations of 
LVMI, the urinary albumin-to-creatinine ratio, and PWV with 
SD and coefficient of variation as estimated from  beat-to-beat, 
24-hour ambulatory, and home BP recordings confirmed the 
Table 4. Association of Organ Damage With Level and Variability of Systolic Blood Pressure Derived From Home Self-Measurement
Correlate (Approximate SD) Model Left Ventricular Mass Index, g/m2 Albumin-to-Creatinine Ratio, mg/mmol Pulse Wave Velocity, m/s
SBP (+11 mm Hg) None 1.089 (–1.606 to 3.784) 1.274 (1.143 to 1.419)* 0.363 (0.212 to 0.514)*
VIM 1.111 (–1.606 to 3.828) 1.274 (1.143 to 1.419)* 0.363 (0.212 to 0.514)*
MMD 1.056 (–1.704 to 3.816) 1.302 (1.169 to 1.451)* 0.363 (0.212 to 0.514)*
ARV 1.089 (–1.628 to 3.806) 1.288 (1.156 to 1.435)* 0.396 (0.245 to 0.547)*
VIM (+2 U) None 0.278 (–2.352 to 2.908) 0.947 (0.856 to 1.049) –0.022 (–0.179 to 0.135)
SBP 0.338 (–2.300 to 2.976) 0.940 (0.852 to 1.037) –0.034 (–0.183 to 0.115)
MMD (+6 mm Hg) None 0.396 (–2.391 to 3.183) 1.012 (0.910 to 1.125) 0.072 (–0.081 to 0.225)
SBP 0.210 (–2.624 to 3.044) 0.942 (0.847 to 1.047) –0.030 (–0.183 to 0.123)
ARV (+2 mm Hg) None 0.962 (–1.743 to 3.667) 1.008 (0.914 to 1.112) –0.046 (–0.195 to 0.103)
SBP 0.962 (–1.747 to 3.671) 0.951 (0.862 to 1.049) –0.134 (–0.279 to 0.011)
Model indicates which systolic index was entered into the models in addition to the predictor variable per se. None indicates that no systolic index was entered in 
addition to the studied predictor variable. Effect sizes (95% confidence interval) express the change in the target organ damages with a 1-SD increase in the systolic 
predictors. All models were adjusted for sex, age, body mass index, heart rate, plasma glucose, serum cholesterol, smoking, and drinking. ARV indicates average real 
variability; MMD, the difference of maximum minus minimum systolic blood pressure; SBP, systolic blood pressure; and VIM, variability independent of the mean. 
Significance of the estimates: *P<0.001.
Table 3. Association of Organ Damage With Level and Variability of Systolic Blood Pressure Derived From 24-Hour Ambulatory 
Monitoring
Correlate (Approximate SD) Model Left Ventricular Mass Index, g/m2
Albumin-to-Creatinine  
Ratio, mg/mmol Pulse Wave Velocity, m/s
SBP (+12 mm Hg) None 3.216 (0.605 to 5.827)‡ 1.241 (1.103 to 1.397)* 0.420 (0.255 to 0.585)*
VIM 3.204 (0.570 to 5.838)‡ 1.241 (1.103 to 1.397)* 0.420 (0.255 to 0.585)*
MMD 3.156 (0.357 to 5.955)‡ 1.271 (1.130 to 1.430)* 0.360 (0.195 to 0.525)*
ARV 3.792 (1.017 to 6.567)† 1.287 (1.143 to 1.448)* 0.444 (0.279 to 0.609)*
VIM (+3 U) None 0.363 (–2.525 to 3.191) 0.939 (0.845 to 1.044) 0.165 (0.006 to 0.324)‡
SBP 0.249 (–2.550 to 3.060)  0.933 (0.839 to 1.448) 0.156 (0.003 to 0.309)‡
MMD (+14 mm Hg) None 1.330 (–1.551 to 4.211) 0.986 (0.883 to 1.101) 0.280 (0.115 to 0.445)*
SBP 0.168 (–2.850 to 3.186) 0.932 (0.835 to 1.041) 0.168 (0.003 to 0.333)‡
ARV (+2 mm Hg) None –0.696 (–4.169 to 2.777) 1.021 (0.883 to 1.161) 0.126 (–0.078 to 0.330)
SBP –2.300 (–5.883 to 1.283) 0.898 (0.776 to 1.038) –0.090 (–0.302 to 0.122)
Model indicates which systolic index was entered into the models in addition to the predictor variable per se. None indicates that no systolic index was entered in 
addition to the studied predictor variable. Effect sizes (95% confidence interval) express the change in the target organ damages with a 1-SD increase in the systolic 
predictors. All models were adjusted for sex, age, body mass index, heart rate, plasma glucose, serum cholesterol, and smoking and drinking. ARV indicates average 
real variability; MMD, the difference of maximum minus minimum systolic blood pressure; SBP, systolic blood pressure; and VIM, variability independent of the mean.
Significance of the estimates: *P<0.001; †P<0.01; and ‡P<0.05.
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findings reported in Tables 2, 3, and 4. In all of these analyses 
the variance inflation factor was <1.31. The analyses based on 
a balanced sample for all estimates (n=128) were also confir-
matory (data not shown). Finally, analyses based on diastolic 
BP generated results similar to those based on systolic BP, 
although in general associations were weaker and significance 
levels lower (Table S9).
Discussion
To our knowledge, our article is the first that in the same par-
ticipants addressed the association of organ damage with BP 
level and variability over differing periods, covering 10 min-
utes, daytime, nighttime, 24 hours, and 7 days. The key finding 
of our study was that the 3 indices of 10-minute BP vari-
ability were associated with LVMI independent of level and 
 10-minute MMD also with the urinary  albumin-to-creatinine 
ratio. Furthermore, levels of the 24-hour and home BPs were 
associated with organ damage, whereas variability derived 
from such recordings was not associated with organ damage 
except for the relation of PWV with VIM and MMD derived 
from 24-hour ambulatory monitoring.
There is a physiological corollary possibly explaining our 
findings.13 BP variability over very short (beat-to-beat) or short 
(within 24 hours) periods reflect the influence of central and 
reflex autonomic nervous modulation, the elastic properties 
of the central arteries, circulating hormones, blood viscosity, 
and psychological stress.13 Although intermittent ambula-
tory BP monitoring is less precise in capturing short-term BP 
variations as compared with beat-to-beat recordings,13 we 
previously demonstrated that BP variability by ambulatory 
monitoring contributed to the prediction of hard cardiovascu-
lar outcomes, albeit to a small amount.10 Longer term BP vari-
ability, such as captured by self-measurement at home, does 
not entirely consist of spontaneous BP variations nor reflects 
the same cardiovascular control mechanisms as very short or 
short-term BP variability and is under the influence of behav-
ioral between-day variability.13
Few other studies addressed the risk associated with BP 
variability as captured from beat-to-beat recordings. Parati 
et al1 recorded 24-hour beat-to-beat BP intra-arterially and 
scored target organ damage in 108 untreated hospitalized 
patients. In analyses by quintiles, for nearly any level of the 
24-hour BP, patients whose 24-hour BP variability was below 
average had a lower prevalence and severity of target organ 
damage than those with a higher than average BP variability.1 
Veerman et al18 recorded BP level and variability during 20 
minutes by means of the Finapres Model 5 in 33 untreated 
hypertensive patients. The urinary albumin-to-creatinine ratio 
correlated with diastolic (r=0.37; P=0.037) but not systolic 
BP variability. The associations of LVMI with systolic and 
diastolic BP variability were not significant.18 The drawbacks 
of these previous studies were small sample size,1,18 selection 
of hospitalized participants,1 and categorical instead of contin-
uous analyses.1 In our study, all 3 studied indices of 10-minute 
beat-to-beat BP variability were associated with LVMI inde-
pendent of level and 10-minute MMD also with the urinary 
albumin-to-creatinine ratio. However, the Finometer reliably 
captures BP variation or changes in BP in response to an inter-
vention but might be less reliable in establishing a person’s 
BP level.19 This might explain in our study the absence of 
any association between LVMI and the systolic BP level as 
assessed by beat-to-beat recordings.
Turning to BP variability assessed from intermittent 
24-hour ambulatory recordings, we previously demon-
strated that ≥48 readings are required to compute BP vari-
ability without loss of prognostic information.20 Tatasciore 
et al2 reported in 180 untreated participants that LVMI was 
independently associated with awake systolic BP level and 
variability, whereas the rate of nocturnal (12 hours) micro-
albuminuria was related to awake systolic BP variability, 
but not level. A subsequent article by the same authors in 
an extended group of 309 patients concluded that higher BP 
variability with adjustment for left ventricular mass was asso-
ciated with depressed indices of left ventricular function.21 
Although previous publications consistently demonstrated 
that nighttime BP level is a strong predictor of cardiovascular 
risk,22 the association of nighttime BP variability with target 
organ damage remains to be elucidated. In our current study, 
all 3 measures of target organ were related to the nighttime 
systolic BP level but not variability, which is consistent with 
most,23–25 although not all26 previous studies.
In our current study, aortic PWV independently increased 
with level and VIM or MMD of systolic BP. Because of the 
cross-sectional nature of our study, we cannot distinguish 
cause from effect. We presume that with stiffer central arter-
ies, BP must be more variable, systolic BP, and augmentation 
being buffered less in the large elastic arteries. Moreover, stiff-
ening of the carotid arteries impairs baroreflexes. In 47 nor-
motensive men, Monahan et al27 observed that carotid arterial 
compliance was a strong determinant of baroreflex sensitivity, 
explaining 51% of the total variance. Similarly, 2 other studies 
involving younger28 or older29 healthy volunteers reported an 
inverse association between indexes of carotid stiffening and 
baroreflex sensitivity.
Finally turning to the self-measured BP at home, we noticed 
that none of the indices of target organ damage was associated 
with BP variability, as captured by VIM, MMD, or ARV. The 
Ohasama investigators recently reported that independent of 
morning systolic BP level, morning VIM and ARV predicted 
total and cardiovascular mortality (P≤0.044), whereas morning 
MMD did not predict any end point (P≥0.085).30 However, the 
R2 statistic, a measure for the incremental risk explained by add-
ing BP variability to models already including level and covari-
ables, ranged only from <0.01% to 0.88%.30 The conclusion of 
the Ohasama investigators30 that the indices of BP variability 
derived from home BP do not incrementally predict outcome 
over and beyond BP level is in keeping with our current find-
ings based on the cross-sectional assessment of target organ 
damage. Home BP measurement provides less comprehensive 
information than ambulatory monitoring because substantially 
fewer readings are obtained within a 24-hour time window and 
because responses to an individual’s physical and mental stress-
ors are eliminated by obtaining the home BP measurements 
under standardized conditions in the morning and evening. The 
more restricted information provided by home BP measure-
ment, in comparison with 24-hour ambulatory monitoring, both 
in terms of BP level and variability probably explains why in 
our current study systolic BP on home measurement was not 
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correlated with LVMI and why day-to-day BP variability was 
unrelated to the measures of target organ damage.
Our current study must be interpreted within the context of 
its limitations. First, the present study had a cross-sectional 
design. We assessed only intermediate signs of target organ 
damage and only 50% of our participants had LVMI mea-
sured. Our current observations can therefore not be extrap-
olated to the incidence of hard cardiovascular or renal end 
points. Second, our study participants were either normoten-
sive individuals or untreated patients with mild hypertension, 
who were at relatively low cardiovascular risk. The low num-
ber of patients with left ventricular hypertrophy, microalbu-
minuria, or abnormally increased PWV made a meaningful 
logistic analyses with binary outcomes impossible. However, 
continuous traits, as used in the current article, provide fuller 
information than binary traits dichotomized by criteria that are 
often applied in clinical practice but always remain arbitrary 
to some extent. Notwithstanding this principle, future stud-
ies in  high-risk patients with binary outcomes, such as left 
ventricular hypertrophy, microalbuminuria, or abnormally 
increased PWV, are warranted to confirm our current find-
ings. Third, among our study participants, there was large dis-
crepancy between the prevalence of hypertension as assessed 
by office and  out-of-the-office BP measurement. Based 
on 24-hour ambulatory BP monitoring, normotension and 
 white-coat, masked, and sustained hypertension had a preva-
lence of 32.0%, 4.7%, 41.0% and 22.3%, respectively. Based 
on the self-measured BP at home, these frequencies were 
51.6%, 8.6%, 21.5%, and 18.4%, respectively. These findings 
probably reflect the indications for referral of our patients and 
highlight the need for a replication of our findings in a ran-
domly selected population sample.
Perspectives
Beat-to-beat recordings, even as short as 10 minutes, out-
perform 24-hour ambulatory and home monitoring in the 
assessment of target organ damage in relation to BP variabil-
ity, whereas the opposite is true for evaluating the contribu-
tion of BP level to organ damage. Current knowledge on the 
mechanisms of short-term BP variability is limited, and addi-
tional studies will be needed to improve our understanding 
of its potential determinants and prognostic implications. If 
confirmed in prospective studies with hard cardiovascular out-
comes, our current findings potentially identified an easy way 
to assess short-term BP variability as a risk factor at least in 
individuals not on antihypertensive drug treatment.
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What Is New?
•	This study examined for the first time the independent associations of 
organ damage with level and variability of systolic blood pressure (BP) as 
captured from 10-minute beat-to-beat, 24-hour ambulatory, and 7-day 
home recordings.
What Is Relevant?
•	Whether naturally occurring BP variability predicts risk over and beyond 
BP level remains debated.
•	Beat-to-beat recordings might be optimal to capture short-term BP vari-
ability, whereas intermittent ambulatory BP monitoring is less precise.
Summary
While accounting for BP level, associations of target organ dam-
age with BP variability were readily detectable in beat-to-beat BP 
recordings, least noticeable in home BP recordings, with  24-hour 
ambulatory monitoring being informative only for pulse wave ve-
locity.
Novelty and Significance
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Expanded Methods  
Blood Pressure Measurement  
For all BP measurements at the brachial artery, we applied the recommendations of 
the European Society of Hypertension and adjusted cuff size to arm circumference.1  
We programmed validated oscillometric SpaceLabs 90217 monitors (SpaceLabs, 
Redmond, Washington) to obtain BP readings at 20-minute intervals from 06:00 to 
22:00 and at 30-minute intervals from 22:00 to 06:00.  All recordings covered more 
than 20 hours and included at least 70% of the programmed readings, without inter-
val between readings longer than 2 hours, and were sparsely edited.  The 24-h BP 
means were weighted for the time interval between consecutive readings.2  Ambula-
tory hypertension was a 24-h BP averaging 130 mm Hg systolic or 80 mm Hg dia-
stolic or more.1  Office BP was measured with the Omron HEM-7051 monitor (Omron 
HealthCare, Kyoto, Japan).3  After the participants had rested in the sitting position 
for at least 10 minutes, three consecutive readings were obtained.  For analysis, the 
three readings were averaged.  Office hypertension was a BP of at least 140 mm Hg 
systolic or 90 mm Hg diastolic.  Participants obtained BP readings at home in tripli-
cate in the morning before breakfast and again three times in the evening before go-
ing to sleep during 7 consecutive days.  They did the self-measurements in the sitting 
position, using validated Omron HEM-7051 monitors.3  The home BP was the aver-
age of all available readings.  Home hypertension was a BP of 135 mm Hg systolic or 
85 mm Hg diastolic or more.1   
Within 7 days after 24-h BP monitoring, we recorded the beat-to-beat finger BP for 
10 minutes after participants had rested for at least 10 minutes in the supine position.  
We used the validated4,5 Finometer device (Finapres Medical System, Amsterdam, 
The Netherlands) that implements the volume-clamp method developed by Penáz.6  
The finger BP was calibrated using an upper arm cuff measurement and return to 
flow technology.6  For analysis, we discarded the first minute of the recordings.    
Assessment of Target Organ Damage  
As described in detail elsewhere,7 left ventricular mass index by echocardiography 
(n=128), the urinary albumin-to-creatinine ratio (n=256), and aortic pulse wave veloc-
ity (n=255) were determined as measures of organ damage.  Briefly, echocardio-
grams were obtained according to the recommendations of the American Society of 
Echocardiography,8 using a Phillips IE33 scanner (Phillips, Eindhoven, The Nether-
lands).  A first-morning urine sample was collected for the measurement of the uri-
nary albumin (in milligram) and creatinine (in millimoles) concentrations.  Aortic pulse 
wave velocity was measured by sequential electrocardiogram-gated recordings of the 
arterial pressure waveform at the carotid and femoral arteries using the SphygmoCor 
device (AtCor Medical, West Ryde, New South Wales, Australia).7 
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Other Measurements  
Nurses administered a standardized questionnaire, to inquire about each partici-
pant’s medical history, intake of medications, and smoking and drinking habits.  They 
also measured body height and waist circumference to the nearest 0.5 cm.  Body 
mass index was weight in kilograms divided by the height in meters squared.  Ve-
nous blood samples, collected after overnight fasting, were analyzed by automated 
enzymatic methods for serum cholesterol and plasma glucose.  Diabetes mellitus 
was a fasting plasma glucose level of 7.0 mmol/L9 or higher or use of antidiabetic 
drugs. 
Statistical Analysis  
We assessed BP variability from the variability independent of the mean (VIM),10 the 
difference between maximum and minimum BP (MMD), and average real variability 
(ARV).11  VIM is calculated as the SD divided by the mean to the power x and multi-
plied by the population mean to the power x.10  The values of x for the finger, 24-h 
and home BP were 1.03, 0.61, and 1.11, respectively.  ARV is the average of the ab-
solute differences between consecutive BP measurements.11 
Expanded Results  
We subdivided our study population into normotensive subjects and patients with 
white-coat, masked or sustained hypertension.  Based on 24-ambulatory blood pres-
sure measurement, normotension and white-coat, masked and sustained hyperten-
sion had a prevalence of 32.0%, 4.7%, 41.0% and 22.3%, respectively.  Based on 
the self-measured blood pressure at home, these frequencies we 51.6%, 8.6%, 
21.5% and 18.4%, respectively.  Multivariable-adjusted models not including blood 
pressure on 24-h or home measurement, demonstrated that sustained hypertension 
was associated with increased albumin-to-creatinine ratio (P≤0.01) and pulse wave 
velocity (P<0.001), but not left ventricular mass index (P≥0.47).  However, introduc-
ing systolic blood pressure on 24-h or home measurement removed the significance 
of the aforementioned associations (P≥0.10). 
The median number of cardiac cycles in beat-to-beat recordings was 685 (5th to 
95th percentile interval, 502–771).  The median number of BP readings averaged for 
analysis was 60 (5th to 95th percentile interval, 49–64; range 43–65) for the 24-h BP 
and 42 (5th to 95th percentile interval, 36–42; range, 24–42) for the home BP.  There 
was no preference in the terminal digits in the home BP measurement (P=0.78).  The 
number of identical systolic and diastolic readings in the morning or evening was less 
than 4% on any of the 7 measurement days (Table S1).   
 
References: 
1. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers 
M, Padfield P, Palatini P, Parati G, Pickering T, Redón J, Staessen J, Stergiou G, 
Verdecchia P, on behalf of the European Society of Hypertension Working Group 
4 
 
on Blood Pressure Monitoring. European Society of Hypertension 
recommendations for conventional, ambulatory and home blood pressure 
measurement. J Hypertens.  2003;21:821-848. 
2. Thijs L, Staessen J, Fagard R. Analysis of the diurnal blood pressure curve. High 
Blood Press Cardiovasc Prev.  1992;1:17-28. 
3. El Assaad MA, Topouchian JA, Asmar RG. Evaluation of two devices for self-
measurement of blood pressure according to the international protocol : the 
Omron M5-I and the Omron 705IT. Blood Press Monit.  2003;8:127-133. 
4. Imholz BP, Langewouters GJ, van Montfrans GA, Parati G, van Goudoever J, 
Wesseling KH, Wieling W, Mancia G. Feasibility of ambulatory, continuous 24-
hour finger arterial pressure recording. Hypertension.  1993;21:65-73. 
5. Schutte AE, Huisman HW, van Rooyen JM, Malan NT, Schutte R. Validation of 
the Finometer device for measurement of blood pressure in black women. J Hum 
Hypertens.  2004;18:79-84. 
6. Penáz J. Criteria for set point estimation in the volume clamp method of blood 
pressure measurememt. Physiol Res.  1992;41:5-10. 
7. Wei FF, Li Y, Zhang L, Xu TY, Ding FH, Staessen JA, Wang JG. Association of 
target organ damage with 24-hour systolic and diastolic blood pressures and 
hypertension subtypes in untreated Chinese. Hypertension. 2014; 
http://hyper.ahajournals.org/content/early/2013/11/18/HYPERTENSIONAHA.113.
01940.reprint. Accessed Nov 18, 2013. 
8. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, 
Morehead A, Kitzman D, Oh J, Quinones M, Schiller NB, Stein JH, Weissman 
NJ. American Society of Echocardiography recommendations for use of 
echocardiography in clinical trials.  A report from the American Society of 
Echocardiography's Guidelines and Standard Committee and the Task Force on 
Echocardiography in Clinical Trials. J Am Soc Echocardiogr.  2004;17:1086-
1119. 
9. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 
Report of the expert committee on the diagnosis and classification of diabetes 
mellitus. Diabetes Care.  2003;26 (suppl 1):S5-S20. 
10. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, 
Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic 
blood pressure, and episodic hypertension. Lancet.  2010;375:895-905. 
11. Mena L, Pintos S, Queipo NV, Aizpúrua JA, Maestre G, Sulbarán T. A reliable 
index for the prognostic significance of blood pressure variability. J Hypertens.  
2005;23:505-511. 
5 
 
Table S1.  Within-Patient Number Preference for Home Blood Pressure Readings  
Day  
 Morning Blood Pressure Measurements   Evening Blood Pressure Measurements  
 Systolic   Diastolic   Systolic   Diastolic  
 Na  Nb  %   Na  Nb  %   Na  Nb  %   Na  Nb  %  
1   187  1  1   187  2  1   252  2  1   252  4  2  
2   254  1  0   254  1  0   254  0  0   254  2  1  
3   254  0  0   254  4  2   254  0  0   254  3  1  
4   251  2  1   251  3  1   253  1  0   253  4  2  
5   253  2  1   253  6  2   249  2  1   249  6  2  
6   250  0  0   250  0  0   249  0  0   249  4  2  
7   253  2  1   253  3  1   222  1  0   222  8  4  
Day indicates the order of the measurement days.  Na denotes the number of patients with home blood pressure mea-
surement on a specified day.  Nb is the number of patients with 3 identical readings.    
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Table S2.  Correlations between Systolic Indices Within and Across Types of Blood Pressure Recordings  
Correlate 
Beat-to-Beat  24-H Monitoring   Home Self-Measurement  
SBP  VIM  MMD  ARV  SBP  VIM  MMD  ARV   SBP  VIM  MMD  ARV  
Beat-to-Beat               
SBP  1  0.005  0.100  0.298‡ 0.497‡     0.505‡    
VIM   1   0.691‡ 0.444‡  0.152*     0.008    
MMD    1  0.425‡   0.069      –0.017  
ARV     1     0.130*     0.004  
24-h Monitoring                
SBP      1 0.004 0.295‡ 0.339‡  0.702‡    
VIM        1 0.816‡ 0.450‡   0.130*   
MMD        1 0.515‡    0.174†  
ARV          1     0.151* 
Home Self-
Measurement  
             
SBP           1 –0.008 0.230‡ 0.185† 
VIM            1 0.944‡ 0.755‡ 
MMD             1 0.784‡ 
ARV              1 
Abbreviations: SBP, systolic blood pressure; VIM, variability independent of the mean; MMD, the difference of maximum minus 
minimum systolic blood pressure; ARV, average real variability.   Values are Pearson correlation coefficients.   
Significance of the correlation coefficients: * P≤0.05; † P≤0.01; and ‡ P≤0.001.   
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Table S3.   Determinants of the Indices of Systolic Variability by Type of Blood Pressure Measurement (starts)  
Regression Parameters Variability Independent 
of the Mean (unit)  
 Maximum–Minimum  
Difference (mm Hg)  
 Average Real Variability 
(mm Hg)  
Beat-to-Beat Recordings       
R2  0.023   0.046   0.183  
Effect size       
Female sex  …  …  0.379 (0.163 to 0.595)‡  
Age (+10 years)  …  –2.370 (–5.192 to 0.452)   –0.110 (–0.208 to –0.012)* 
Systolic pressure (+13 mm Hg)  …  2.886 (–0.044 to 5.816)   0.273 (0.171 to 0.375)‡  
Body mass index (+3 kg/m2 )  …  3.732 (0.657 to 6.807)*   0.147 (0.035 to 0.259)*  
Plasma glucose (+1 mmol/L)  0.385 (0.073 to 0.697)*   …  … 
Smoking (0,1)  …  …  –0.011 (–0.021 to –0.001)* 
24-h Monitoring       
R2  0.031   0.115   0.262  
Effect size       
Age (+10 years) 0.400 (0.047 to 0.753)*   1.330 (–0.297 to 2.957)   0.530 (0.354 to 0.706)‡  
Systolic pressure (+12 mm Hg) …  4.200 (2.530 to 5.870)‡   0.564 (0.376 to 0.332)‡  
Heart rate (+8 beat/minute) …  …  0.144 (–0.044 to 0.311)  
Total cholesterol (+1 mmol/L) 0.376 (–0.053 to 0.805)   2.190 (0.299 to 4.081)*   0.194 (–0.016 to 0.404)  
Drinking (0,1) …  …  0.369 (–0.101 to 0.839)  
Smoking (0,1) …  …  –0.537 (–1.04 to –0.033)*  
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Table S3.   Determinants of the Indices of Systolic Variability by Type of Blood Pressure Measurement (continues)   
Regression parameters   Variability Indepen-
dent of the Mean (unit) 
 Maximum–Minimum 
Difference (mm Hg)  
 Average Real Variability 
(mm Hg )  
Home Self-Measurement        
R2    0.107   0.170   0.134  
Effect size        
Female sex  1.195 (0.695 to 1.695)‡  3.252 (1.749 to 4.755)‡  1.136 (0.615 to 1.657)‡  
Age (+10 years)  0.270 (0.015 to 0.525)*  0.740 (–0.005 to 1.485)  … 
Systolic pressure (+11 mm Hg)  …  1.760 (1.049 to 2.471)‡  0.517 (0.258 to 0.776)‡  
Drinking (0,1)  0.643 (–0.065 to 1.351)  1.882 (–0.160 to 3.924)  0.659 (–0.060 to 1.378)  
Effect sizes (95% confidence interval) express the change in the systolic indices associated with 1-SD increase in the base-
line variables. R2 is the coefficient of multiple determination and indicates the percentage of variance explained by the 
whole model.  The variables considered in the stepwise regression procedure included: sex, age, body mass index, systolic 
blood pressure, heart rate, smoking and drinking, serum total cholesterol, and fasting plasma glucose.  Variables were al-
lowed to enter and stay in the model with the P-value set at 0.15.   
Significance of the effect sizes: * P≤0.05; † P≤0.01; and ‡ P≤0.001.   
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Table S4.   Association of Organ Damage with Level and Variability of Daytime Ambulatory Systolic Blood Pres-
sure  
Correlate   
(approximate SD)   
 Model  Left Ventricular Mass  
Index (g/m2)  
Albumin-to-Creatinine 
Ratio (mg/mmol)  
Pulse Wave Velocity  
(m/s)  
SBP (+13 mm Hg)   None   3.250 (0.575 to 5.925)*  1.215 (1.097 to 1.346)‡ 0.455 (0.302 to 0.608)‡  
  VIM   3.224 (0.523 to 5.925)*  1.215 (1.097 to 1.346)‡ 0.455 (0.302 to 0.608)‡  
  MMD   2.990 (0.187 to 5.793)*  1.215 (1.097 to 1.346)‡ 0.403 (0.250 to 0.556)‡  
  ARV   3.640 (0.786 to 6.494)*  1.231 (1.084 to 1.398)‡ 0.481 (0.303 to 0.659)‡  
VIM (+3 units)   None   1.005 (–2.064 to 4.074)  1.000 (0.884 to 1.131) 0.180 (–0.008 to 0.368)* 
  SBP   0.849 (–2.173 to 3.871)  0.985 (0.871 to 1.114) 0.147 (–0.029 to 0.323)  
MMD (+13 mm Hg)   None   1.807 (–0.945 to 4.559)  1.040 (0.939 to 1.151) 0.286 (0.133 to 0.439)‡  
  SBP   0.988 (–1.840 to 3.816)  0.987 (0.891 to 1.093) 0.195 (0.042 to 0.348)*  
ARV (+2 mm Hg)    None   0.010 (–2.871 to 2.891)  1.037 (0.925 to 1.162) 0.144 (–0.028 to 0.316)  
  SBP   –1.242 (–4.225 to 1.741) 0.951 (0.842 to 1.075) –0.052 (–0.228 to 0.124) 
Abbreviations: SBP, systolic blood pressure; VIM, variability independent of the mean; MMD, the difference of maximum 
minus minimum systolic blood pressure; ARV, average real variability.  Daytime blood pressure (6 AM – 10 PM) was obtained 
by 24-h ambulatory monitoring excluding the transition periods in the morning and evening when blood pressure rapidly 
changes.  Model indicates which systolic index was entered into the models in addition to the predictor variable per se.  
None indicates that no other systolic index was entered in addition to the studied predictor variable.  Effect sizes (95% con-
fidence interval) express the change in the target organ damages with a 1-SD increase in the systolic predictors.  All mod-
els were adjusted for sex, age, body mass index, heart rate, plasma glucose, serum cholesterol, smoking and drinking.  
Significance of the estimates: * P≤0.05; † P≤0.01; and ‡ P≤0.001.   
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Table S5.   Association of Organ Damage with Level and Variability of Nighttime Ambulatory Systolic Blood Pres-
sure  
Correlate 
(approximate SD)   
 Model  Left Ventricular Mass   
Index (g/m2)  
Albumin-to-Creatinine 
Ratio (mg/mmol)  
Pulse Wave Velocity  
(m/s)  
SBP (+12 mm Hg)   None   2.712 (0.125 to 5.299)*  1.241 (1.130 to 1.363)‡  0.264 (0.099 to 0.429)‡  
  VIM   2.748 (0.161 to 5.335)*  1.226 (1.116 to 1.347)‡  0.264 (0.099 to 0.429)‡  
  MMD   3.000 (0.342 to 5.658)*  1.256 (1.143 to 1.380)‡  0.276 (0.111 to 0.441)‡  
  ARV   3.012 (0.425 to 5.599)*  1.256 (1.143 to 1.380)‡  0.276 (0.111 to 0.441)‡  
VIM (+4 units)   None   –1.252 (–4.427 to 1.923)  0.916 (0.814 to 1.030) –0.112 (–0.292 to 0.068) 
  SBP   –1.400 (–4.536 to 1.736)  0.923 (0.820 to 1.039) –0.104 (–0.284 to 0.076) 
MMD (+12 mm Hg)   None   –0.732 (–3.554 to 2.090)  0.931 (0.827 to 1.047) –0.048 (–0.213 to 0.117) 
  SBP   –1.440 (–4.286 to 1.406)  0.898 (0.817 to 0.986) –0.096 (–0.261 to 0.069) 
ARV (+2 mm Hg)    None   –1.518 (–2.302 to –0.734) 0.942 (0.864 to 1.026) –0.004 (–0.137 to 0.129) 
  SBP   –1.898 (–2.329 to –1.467)  0.918 (0.842 to 1.000)*  –0.036 (–0.165 to 0.093) 
Abbreviations: SBP, systolic blood pressure; VIM, variability independent of the mean; MMD, the difference of maximum 
minus minimum systolic blood pressure; ARV, average real variability.  Nighttime blood pressure (10 PM – 6AM) was ob-
tained by 24-h ambulatory monitoring excluding the transition periods in the morning and evening when blood pressure ra-
pidly changes.  Model indicates which systolic index was entered into the models in addition to the predictor variable per se.  
None indicates that no other systolic index was entered in addition to the studied predictor variable.  Effect sizes (95% con-
fidence interval) express the change in the target organ damages with a 1-SD increase in the systolic predictors.  All mod-
els were adjusted for sex, age, body mass index, heart rate, plasma glucose, serum cholesterol, smoking and drinking.  
Significance of the estimates: * P≤0.05; † P≤0.01; and ‡ P≤0.001.   
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Table S6.   Association of Organ Damage with Level and Variability of Morning Systolic Blood Pressure Self-
measured at Home 
Correlate 
 (approximate SD)   
 Mod
el  
 Left Ventricular Mass   
Index (g/m2)  
Albumin-to-Creatinine 
Ratio (mg/mmol)  
Pulse Wave Velocity  
(m/s)  
SBP (+12 mm Hg)   None  0.876 (–2.064 to 3.816)  1.271 (1.130 to 1.430)‡  0.360 (0.195 to 0.525)‡  
  VIM   0.924 (–2.016 to 3.864) 1.271 (1.130 to 1.430)‡  0.360 (0.195 to 0.525)‡  
  MMD  0.840 (–2.100 to 3.780)  1.287 (1.143 to 1.448)‡  0.360 (0.195 to 0.525)‡  
  ARV   0.888 (–2.052 to 3.828) 1.287 (1.143 to 1.448)‡  0.372 (0.207 to 0.537)‡  
VIM (+2 units)   None  0.566 (–2.045 to 3.177)  0.963 (0.873 to 1.062) 0.010 (–0.139 to 0.159) 
  SBP   0.624 (–1.998 to 3.246)  0.961 (0.875 to 1.055)  0.006 (–0.135 to 0.147)  
MMD (+6 mm Hg)   None  0.858 (–2.000 to 3.716)  0.982 (0.883 to 1.092) 0.042 (–0.111 to 0.195)   
  SBP   0.822 (–2.036 to 3.680)  0.953 (0.857 to 1.060) 0.0001 (–0.153 to 0.153)  
ARV (+2 mm Hg)    None  1.064 (–1.382 to 3.510)  1.010 (0.927 to 1.101) –0.032 (–0.161 to 0.097)  
  SBP   1.068 (–1.386 to 3.522)  0.988 (0.910 to 1.073) –0.064 (–0.189 to 0.061)  
Abbreviations: SBP, systolic blood pressure; VIM, variability independent of the mean; MMD, the difference of maximum 
minus minimum systolic blood pressure; ARV, average real variability.  Morning blood pressure was obtained by self-
measurement at home.  Model indicates which systolic index was entered into the models in addition to the predictor varia-
ble per se.  None indicates that no other systolic index was entered in addition to the studied predictor variable.  Effect siz-
es (95% confidence interval) express the change in the target organ damages with a 1-SD increase in the systolic predic-
tors.  All models were adjusted for sex, age, body mass index, heart rate, plasma glucose, serum cholesterol, smoking and 
drinking.  Significance of the estimates: * P≤0.05; † P≤0.01; and ‡ P≤0.001.   
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Table S7.   Association of Organ Damage with Level and Variability of Evening Systolic Blood Pressure Self-
measured at Home 
Correlate 
(approximate SD)   
 Model  Left Ventricular Mass   
Index (g/m2)  
Albumin-to-Creatinine 
Ratio (mg/mmol)  
 Pulse Wave Velocity  
(m/s)  
SBP (+12 mm Hg)   None   1.380 (–1.301 to 4.061)  1.287 (1.171 to 1.413)‡  0.348 (0.207 to 0.489)‡  
  VIM   1.320 (–1.385 to 4.025)  1.287 (1.171 to 1.413)‡  0.348 (0.207 to 0.489)‡  
  MMD   1.512 (–1.216 to 4.240)  1.318 (1.200 to 1.448)‡  0.372 (0.207 to 0.537)‡  
  ARV   1.392 (–1.313 to 4.097)  1.318 (1.200 to 1.448)‡  0.384 (0.219 to 0.549)‡  
VIM (+3 units)   None   –0.744 (–3.619 to 2.131)  0.914 (0.822 to 1.016)  –0.042 (–0.201 to 0.117) 
  SBP   –0.588 (–3.481 to 2.305)  0.900 (0.815 to 0.995)*  –0.063 (–0.216 to 0.090) 
MMD (+9 mm Hg)   None   –0.720 (–3.807 to 2.367)  0.991 (0.891 to 1.102)  0.054 (–0.105 to 0.213)  
  SBP   –0.990 (–4.112 to 2.132)  0.914 (0.822 to 1.016)  –0.063 (–0.222 to 0.096) 
ARV (+4 mm Hg)    None   –0.160 (–3.492 to 3.172)  0.972 (0.871 to 1.085)  –0.032 (–0.204 to 0.140) 
  SBP   –0.248 (–3.588 to 3.092)  0.901 (0.807 to 1.006)  –0.140 (–0.305 to 0.025) 
Abbreviations: SBP, systolic blood pressure; VIM, variability independent of the mean; MMD, the difference of maximum 
minus minimum systolic blood pressure; ARV, average real variability.  Evening blood pressure was obtained by self-
measurement at home.  Model indicates which systolic index was entered into the models in addition to the predictor varia-
ble per se.  None indicates that no other systolic index was entered in addition to the studied predictor variable.  Effect siz-
es (95% confidence interval) express the change in the target organ damages with a 1-SD increase in the systolic predic-
tors.  All models were adjusted for sex, age, body mass index, heart rate, plasma glucose, serum cholesterol, smoking and 
drinking. Significance of the estimates: * P≤0.05; † P≤0.01; and ‡ P≤0.001.   
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Table S8.   Association of Organ Damage with Classical Indexes of Blood Pressure Variability According to Re-
cording Technique (Starts)  
Correlate 
(approximate SD)   
 Model  Left Ventricular Mass  
Index (g/m2)  
Albumin-to-Creatinine 
Ratio (mg/mmol)  
Pulse Wave Velocity  
(m/s)  
Beat-to-Beat Recording        
SBP (+ 13 mm Hg)   None   1.209 (–1.619 to 4.037)    1.169 (1.055 to 1.294)† 0.689 (0.562 to 0.816)‡ 
  SD   0.824 (–1.901 to 3.548) 1.147 (1.027 to 1.280)* 0.701 (0.560 to 0.841)‡ 
  CV   1.850 (–0.901 to 4.600)  1.164 (1.047 to 1.294)† 0.673 (0.537 to 0.808)‡ 
SD (+ 2.6 mm Hg)   None   4.176 (1.328 to 7.024)† 1.099 (0.988 to 1.221) 0.074 (–0.083 to 0.232) 
  SBP   4.097 (1.229 to 6.965)† 1.060 (0.951 to 1.182) –0.107 (–0.245 to 0.031) 
CV (+ 1.8%)  None   3.579 (0.921 to 6.237)† 1.064 (0.957 to 1.183) –0.085 (–0.242 to 0.072) 
  SBP   3.885 (1.196 to 6.573)† 1.063 (0.958 to 1.231) –0.091 (–0.224 to 0.043) 
24-h Ambulatory  
Monitoring  
      
SBP (+ 12 mm Hg)   None   3.216 (0.605 to 5.827)*    1.241 (1.103 to 1.397)‡ 0.420 (0.255 to 0.585)‡ 
  SD   3.107 (0.388 to 5.826)* 1.259 (1.128 to 1.405)‡ 0.368 (0.208 to 0.528)‡ 
  CV   3.183 (0.559 to 5.807)* 1.220 (1.097 to 1.358)‡ 0.433 (0.278 to 0.588)‡ 
SD (+ 3.1 mm Hg)   None   1.095 (–1.721 to 3.912) 0.986 (0.888 to 1.096) 0.252 (0.096 to 0.408)† 
  SBP   0.120 (–2.777 to 3.018) 0.927 (0.834 to 1.031) 0.154 (–0.003 to 0.310) 
CV (+ 2.4%)   None   –0.156 (–2.992 to 2.681) 0.914 (0.823 to 1.016) 0.102(–0.058 to 0.261) 
  SBP     0.324 (–2.485 to 3.133) 0.937 (0.845 to 1.041) 0.159 (0.007 to 0.311)* 
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Table S8.   Association of Organ Damage with Classical Indexes of Blood Pressure Variability According to Re-
cording Technique (Continues)  
Correlate 
(approximate SD)   
 Model  Left Ventricular Mass  
Index (g/m2)  
Albumin-to-Creatinine 
Ratio (mg/mmol)  
Pulse Wave Velocity  
(m/s)  
Home Self-
Measurement  
      
SBP (+ 11 mm Hg)   None   1.089 (–1.606 to 3.784)    1.274 (1.143 to 1.419)‡ 0.363 (0.212 to 0.514)‡ 
  SD   1.027 (–1.843 to 3.897) 1.312 (1.179 to 1.461)‡ 0.381 (0.220 to 0.541)‡ 
  CV   1.135 (–1.695 to 3.965) 1.292 (1.165 to 1.432)‡ 0.372 (0.217 to 0.527)‡ 
SD (+ 2.2 mm Hg)   None   0.753 (–2.152 to 3.657) 1.004 (0.899 to 1.121) 0.066 (–0.098 to 0.230) 
  SBP   0.571 (–2.384 to 3.525) 0.931 (0.834 to 1.039) –0.040 (–0.204 to 0.123) 
CV (+ 1.7%)  None   0.343 (–2.487 to 3.174) 0.949 (0.850 to 1.061) –0.014 (–0.179 to 0.152) 
  SBP   0.381 (–2.456 to 3.218) 0.935 (0.841 to 1.040) –0.036 (–0.195 to 0.123) 
Abbreviations: SBP, systolic blood pressure; SD, standard deviation; CV, coefficient of variation.  Model indicates which 
systolic index was entered into the models in addition to the predictor variable per se.  None indicates that no other sys-
tolic index was entered in addition to the studied predictor variable.  Effect sizes (95% confidence interval) express the 
change in the target organ damages with a 1-SD increase in the systolic predictors.  All models were adjusted for sex, 
age, body mass index, heart rate, plasma glucose, serum cholesterol, smoking and drinking.  
Significance of the estimates: * P≤0.05; † P≤0.01; and ‡ P≤0.001. 
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Table S9.   Association of Organ Damage with Indexes of Diastolic Blood Pressure Variability According to Re-
cording Technique (Starts)  
Correlate 
(approximate SD)   
 Model  Left Ventricular Mass   
Index (g/m2) 
Albumin-to-Creatinine 
Ratio (mg/mmol)  
Pulse Wave Velocity  
(m/s)  
Beat-to-Beat Recording        
DBP (+ 8 mm Hg)   None   –0.003 (–2.749 to 2.743)   1.117 (0.997 to 1.254)   0.298 (0.132 to 0.464)‡ 
  VIM     0.263 (–2.489 to 3.014)   1.122 (1.000 to 1.257)*   0.302 (0.135 to 0.469)‡ 
  MMD    0.031 (–2.698 to 2.759)   1.113 (0.995 to 1.245)   0.295 (0.129 to 0.461)‡ 
  ARV  –0.049 (–2.788 to 2.689)   1.116 (0.995 to 1.251)   0.295 (0.128 to 0.461)‡ 
VIM (+ 1.8 units)   None     1.800 (–0.510 to 4.110)   1.051 (0.946 to 1.169)   0.050 (–0.106 to 0.207) 
  DBP     1.828 (–0.510 to 4.165)   1.058 (0.952 to 1.176)   0.066 (–0.087 to 0.220) 
MMD (+ 18 mmHg)  None     2.033 (–0.466 to 4.532)   1.179 (1.062 to 1.311)†   0.123 (–0.035 to 0.281) 
  DBP     2.033 (–0.477 to 4.543)   1.177 (1.060 to 1.306)†   0.116 (–0.039 to 0.271) 
ARV (+ 1 mmHg)  None     1.461 (–0.705 to 3.627)   1.040 (0.935 to 1.157)   0.086 (–0.072 to 0.244) 
  DBP    1.462 (–0.715 to 3.638)   1.036 (0.931 to 1.153)   0.075 (–0.080 to 0.230) 
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Table S9.   Association of Organ Damage with Classical Indexes of Blood Pressure Variability According to Re-
cording Technique (Continues)  
Correlate 
(approximate SD)   
 Model  Left Ventricular Mass   
Index (g/m2)  
Albumin-to-Creatinine 
Ratio (mg/mmol)  
Pulse Wave Velocity  
(m/s)  
24-h Ambulatory  
Monitoring  
      
DBP (+ 10 mm Hg)   None     2.927 (–0.024 to 5.878)   1.229 (1.086 to 1.391)†     0.235 (0.049 to 0.422)* 
  VIM     3.088 (  0.092 to 6.085)*   1.224 (1.081 to 1.387)†     0.235 (0.047 to 0.424)* 
  MMD     2.822 (–0.153 to 5.796)   1.228 (1.083 to 1.390)†     0.231 (0.043 to 0.419)* 
  ARV    2.948 (–0.017 to 5.912)   1.226 (1.083 to 1.387)†     0.238 (0.052 to 0.425)* 
VIM (+ 2.0 units)   None     0.506 (–2.411 to 3.423)   0.955 (0.858 to 1.064)   –0.029 (–0.191 to 0.132) 
  DBP     0.986 (–1.931 to 3.902)   0.978 (0.879 to 1.088)   –0.001 (–0.162 to 0.160) 
MMD (+ 9.6 mmHg)   None     1.374 (–1.798 to 4.545)   1.031 (0.921 to 1.154)     0.062 (–0.107 to 0.231) 
  DBP     1.059 (–2.096 to 4.215)   1.013 (0.907 to 1.132)     0.042 (–0.126 to 0.211) 
ARV (+ 1.3 mmHg)   None     0.384 (–2.617 to 3.385)   1.075 (0.964 to 1.198)   –0.077 (–0.240 to 0.085) 
  DBP     0.506 (–2.462 to 3.473)   1.068 (0.961 to 1.189)   –0.084 (–0.245 to 0.077) 
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Table S9.   Association of Organ Damage with Classical Indexes of Blood Pressure Variability According to Record-
ing Technique (Continues)  
Correlate 
(approximate SD)   
 Model  Left Ventricular Mass  
Index (g/m2)  
Albumin-to-Creatinine 
Ratio (mg/mmol)  
Pulse Wave Velocity  
(m/s)  
Home Self-
Measurement  
      
DBP (+ 9 mm Hg)   None       0.445 (–2.573 to 3.463)   1.215 (1.076 to 1.373)†     0.180 (–0.005 to 0.364) 
  VIM       0.530 (–2.524 to 3.584)   1.218 (1.078 to 1.376)†     0.180 (–0.004 to 0.365) 
  MMD       0.461 (–2.573 to 3.495)   1.212 (1.073 to 1.369)†     0.179 (–0.006 to 0.364) 
  ARV      0.441 (–2.593 to 3.476)   1.214 (1.075 to 1.372)†     0.182 (–0.003 to 0.366) 
VIM (+ 1.4 units)   None       0.497 (–2.019 to 3.012)   1.040 (0.934 to 1.158)     0.012 (–0.149 to 0.173) 
  DBP       0.553 (–1.993 to 3.099)   1.046 (0.941 to 1.163)     0.018 (–0.143 to 0.178) 
MMD (+ 3.9 mmHg)   None       0.240 (–2.293 to 2.773)   1.064 (0.955 to 1.184)     0.027 (–0.134 to 0.188) 
  DBP       0.259 (–2.287 to 2.805)   1.054 (0.948 to 1.172)     0.019 (–0.142 to 0.179) 
ARV (+ 1.5 mmHg)   None     –0.097 (–2.868 to 2.675)   1.035 (0.928 to 1.155)   –0.035 (–0.199 to 0.128) 
  DBP     –0.078 (–2.863 to 2.708)   1.028 (0.923 to 1.145)   –0.042 (–0.205 to 0.121) 
Abbreviations: DBP, diastolic blood pressure; SD, standard deviation; CV, coefficient of variation.  Model indicates which di-
astolic index was entered into the models in addition to the predictor variable per se.  None indicates that no other systolic 
index was entered in addition to the studied predictor variable.  Effect sizes (95% confidence interval) express the change in 
the target organ damages with a 1-SD increase in the diastolic predictors.  All models were adjusted for sex, age, body mass 
index, heart rate, plasma glucose, serum cholesterol, smoking and drinking.  
Significance of the estimates: * P≤0.05; † P≤0.01; and ‡ P≤0.001.  
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Figure S1.  Frequency distributions of age in the 256 study participants. Shapiro-Wilk W static for normal test is presented. 
The P value is for departure of the actually observed distribution (solid line) from normality. 
